Literature DB >> 7836076

Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder.

H Mameghan1, R Fisher, J Mameghan, S Brook.   

Abstract

PURPOSE: To assess prognostic factors for bladder relapse and distant failure following definitive radiotherapy for invasive transitional cell carcinoma (TCC) of the bladder. METHODS AND MATERIALS: Retrospective review of patients treated in the period 1977 to 1990 by definitive radiotherapy. The factors studied included age, sex, T stage, histological grade, tumor multiplicity, ureteric obstruction, total radiation dose, and use of neoadjuvant chemotherapy. The endpoints studied were bladder relapse and distant failure.
RESULTS: There were 342 patients with a mean follow-up time of 7.9 years. Bladder relapse was observed in 159 patients. The overall actuarial bladder relapse rate at 5 years was 55% (SE = 3%). Prognostic factors for a higher bladder relapse rate were: tumor multiplicity (p < 0.001), presence of ureteric obstruction (p = 0.001), and higher T stage (p = 0.044). Distant failure occurred in 39 patients. The overall actuarial distant failure rate at 5 years was 28% (SE = 3%). Prognostic factors for a higher distant failure rate were: ureteric obstruction (p = 0.003) and higher T stage (p = 0.030).
CONCLUSION: In our study, patients with invasive bladder TCC fell into distinct prognostic groups determined by the three independent factors, ureteric obstruction, tumor multiplicity, and T stage. These factors provided estimated risks of bladder relapse by 5 years which ranged from 34% to 91%. Knowledge of these prognostic factors can help in the selection of patients more suited for bladder preservation by definitive radiotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 7836076     DOI: 10.1016/0360-3016(94)E0135-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

Review 2.  New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder.

Authors:  P Warde; M K Gospodarowicz
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

3.  Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.

Authors:  Arjun Balar; Dean F Bajorin; Matthew I Milowsky
Journal:  Ther Adv Urol       Date:  2011-06

Review 4.  Bladder cancer: a review of diagnosis and management.

Authors:  M C Metts; J C Metts; S J Milito; C R Thomas
Journal:  J Natl Med Assoc       Date:  2000-06       Impact factor: 1.798

Review 5.  Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review.

Authors:  Georgios Koukourakis; Vassilios Kouloulias; Georgios Zacharias; Anastasia Sotiropoulou-Lontou; Michael Koukourakis
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

Review 6.  Bladder-sparing approaches to invasive disease.

Authors:  Jason A Efstathiou; Anthony L Zietman; Donald S Kaufman; Niall M Heney; John J Coen; William U Shipley
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

7.  Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer.

Authors:  Hitoshi Ikushima; Seiji Iwamoto; Kyohsuke Osaki; Shunsuke Furutani; Kyoh Yamashita; Takashi Kawanaka; Akiko Kubo; Yoshihiro Takegawa; Takaharu Kudoh; Hiroomi Kanayama; Hiromu Nishitani
Journal:  Radiat Med       Date:  2008-04

8.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Authors:  Celestia S Higano; Catherine M Tangen; Wael A Sakr; James Faulkner; Saul E Rivkin; Frederick J Meyers; Maha Hussain; Laurence H Baker; Kenneth J Russell; E David Crawford
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

9.  Conservative treatment of invasive bladder cancer.

Authors:  N J Rene; F B Cury; L Souhami
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

10.  Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder.

Authors:  B S Yadav; S Ghoshal; S C Sharma
Journal:  Indian J Urol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.